These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31844925)

  • 21. A review of three stand-alone topical thrombins for surgical hemostasis.
    Cheng CM; Meyer-Massetti C; Kayser SR
    Clin Ther; 2009 Jan; 31(1):32-41. PubMed ID: 19243705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of IgG Fc-Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy.
    Liu H; Nowak C; Andrien B; Shao M; Ponniah G; Neill A
    Biotechnol Prog; 2017 Sep; 33(5):1173-1181. PubMed ID: 28547754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sterile Filtration of Highly Concentrated Protein Formulations: Impact of Protein Concentration, Formulation Composition, and Filter Material.
    Allmendinger A; Mueller R; Huwyler J; Mahler HC; Fischer S
    J Pharm Sci; 2015 Oct; 104(10):3319-29. PubMed ID: 26149748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.
    van Beers MM; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1473-84. PubMed ID: 23027660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals.
    Srebalus Barnes CA; Lim A
    Mass Spectrom Rev; 2007; 26(3):370-88. PubMed ID: 17410555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.
    Wootla B; Watzlawik JO; Warrington AE; Wittenberg NJ; Denic A; Xu X; Jordan LR; Papke LM; Zoecklein LJ; Pierce ML; Oh SH; Kantarci OH; Rodriguez M
    JAMA Neurol; 2015 Nov; 72(11):1346-53. PubMed ID: 26389734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
    Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.
    Richard J; Prang N
    IDrugs; 2010 Aug; 13(8):550-8. PubMed ID: 20721826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stabilization of a recombinant human epidermal growth factor parenteral formulation through freeze-drying.
    Santana H; Sotolongo J; González Y; Hernández G; Chinea G; Gerónimo H; Amarantes O; Beldarraín A; Páez R
    Biologicals; 2014 Nov; 42(6):322-33. PubMed ID: 25190208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.
    Cleland JL; Lam X; Kendrick B; Yang J; Yang TH; Overcashier D; Brooks D; Hsu C; Carpenter JF
    J Pharm Sci; 2001 Mar; 90(3):310-21. PubMed ID: 11170024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of sucrose and benzyl alcohol on GCSF conformational dynamics revealed by hydrogen deuterium exchange mass spectrometry.
    Zhang J; Banks DD; He F; Treuheit MJ; Becker GW
    J Pharm Sci; 2015 May; 104(5):1592-600. PubMed ID: 25693946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrogen/deuterium exchange-mass spectrometry analysis of high concentration biotherapeutics: application to phase-separated antibody formulations.
    Tian Y; Huang L; Ruotolo BT; Wang N
    MAbs; 2019; 11(4):779-788. PubMed ID: 30890021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development.
    Yu L; Vizel A; Huff MB; Young M; Remmele RL; He B
    J Pharm Biomed Anal; 2006 Oct; 42(4):455-63. PubMed ID: 16828250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological mechanism underlying the immune response to recombinant human protein therapeutics.
    Sauerborn M; Brinks V; Jiskoot W; Schellekens H
    Trends Pharmacol Sci; 2010 Feb; 31(2):53-9. PubMed ID: 19963283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aggregation of Recombinant Monoclonal Antibodies and Its Role in Potential Immunogenicity.
    Ignjatovic J; Svajger U; Ravnikar M; Molek P; Zadravec D; Paris A; Strukelj B
    Curr Pharm Biotechnol; 2018; 19(4):343-356. PubMed ID: 29874996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Creating the next generation of protein therapeutics through rational drug design.
    Szymkowski DE
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):590-600. PubMed ID: 16159021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development.
    Patten PA; Schellekens H
    Dev Biol (Basel); 2003; 112():81-97. PubMed ID: 12762507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody engineering: facing new challenges in cancer therapy.
    Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
    Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.